Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 11/20 | 0.42 |
| ▸ | CNR2 | P34972 | 9/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5349522 | 0.89 | CNR1 (0.39) | CNR1CNR2MAPTKDM4ESMN1; SMN2 | |
| SCHEMBL1438204 | 0.83 | SMN1; SMN2 (0.42) | MAPTKDM4ETSHRSMN1; SMN2POLB | |
| SCHEMBL14513821 | 0.78 | PTGS2 (0.51) | SMN1; SMN2 | |
| SCHEMBL9894376 | 0.78 | SMN1; SMN2 (0.41) | MAPTSMN1; SMN2POLB | |
| SCHEMBL1440045 | 0.77 | GABRA2 (0.47) | MAPTSMN1; SMN2POLB | |
| SCHEMBL1437691 | 0.76 | OPRM1 (0.39) | MAPTKDM4ETSHRSMN1; SMN2NPC1 | |
| SCHEMBL1437481 | 0.76 | RXFP1 (0.42) | MAPTSMN1; SMN2NPC1POLBRAB9A | |
| SCHEMBL1437163 | 0.75 | OPRK1 (0.40) | MAPTKDM4ESMN1; SMN2NPC1POLB | |
| SCHEMBL23027868 | 0.74 | GABRA2 (0.41) | MAPTKDM4ESMN1; SMN2NPC1RAB9A | |
| SCHEMBL5450883 | 0.74 | UGCG (0.41) | MAPTKDM4ETSHRSMN1; SMN2RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070254935-A1 | PYRAZOLE AND IMIDAZOLE COMPOUNDS AND USES THEREOF | PFIZER, INC. | 2007-11-01 | — | — | US | disclosed |
| US-7247628-B2 | Cannabinoid receptor ligands and uses thereof | PFIZER, INC. (US) | 2007-07-24 | — | — | US | disclosed |
| EP-1572662-A1 | PYRAZOLE AND IMIDAZOLE COMPOUNDS AND USES THEREOF | Pfizer Products Inc. (US) | 2005-09-14 | — | — | EP | disclosed |
| WO-2004052864-A1 | PYRAZOLE AND IMIDAZOLE COMPOUNDS AND USES THEREOF | PFIZER PRODUCTS INC. (US) | 2004-06-24 | — | — | WO | disclosed |
| US-20040122074-A1 | Cannabinoid receptor ligands and uses thereof | PFIZER INC. | 2004-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040122074-A1 | Cannabinoid receptor ligands and uses thereof | CNR1, CNR2, GPR18 | CNR1 1/4885CNR2 2/4885MAPT 2213/4885 |
| US-20070254935-A1 | PYRAZOLE AND IMIDAZOLE COMPOUNDS AND USES THEREOF | CNR2, CNR1, GPR18 | CNR1 2/4885CNR2 1/4885MAPT 1892/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.